- Thompson RN
- Hill EM
- Gog JR
- Corrao G
- Franchi M
- Cereda D
- et al.
This study confirms data already available for shorter follow-up periods, which showed a decrease in protection against infection that increased with time since the second dose of vaccine.
- Corrao G
- Franchi M
- Cereda D
- et al.
However, they documented that protection against severe forms of COVID-19 remained, albeit attenuated, with both adenoviral and mRNA vector vaccines.
- Corrao G
- Franchi M
- Cereda D
- et al.
What conclusions can be drawn from this information? First, it is extremely important to continue the vaccination campaign in people who do not yet have vaccine protection, especially if they are at risk of developing severe forms of the disease (elderly, frail, immunocompromised, and people with comorbidities).
- Barda N
- Dagan N
- Cohen C
- et al.
It is therefore necessary to ascertain the main factors that lead these high-risk individuals to not be vaccinated. Vaccine hesitancy is certainly the most important and is due, first, to the media overemphasising the protests of vaccination opponents and the alleged serious side-effects of vaccines, and second, to the spectacularisation of scientific information on COVID-19, which has led to appointed experts spreading contradictory opinions and messages and the public losing confidence in science.
Second, with the emergence of new highly contagious variants such as the omicron variant (B.1.1.529), it seems necessary to encourage the administration of booster doses to high-risk individuals 3–5 months after the second dose and to vaccinate all individuals aged 5 years and older who have not yet received the first dose. The loss of protection against infection by the vaccines and the emergence of the highly transmissible variants prevent the vaccine alone from controlling the pandemic. Hygienic and social distancing measures (frequent hand washing, avoiding physical contact as much as possible, wearing a face mask indoors) and other nonpharmacological measures must be combined with the vaccination strategy.
Regardless of the correct hypothesis, the lesson is the same: countries with high numbers of immunocompromised people, where tracing of variants is rarely done, and where contact with animals potentially susceptible to coronaviruses is possible, need to be quickly involved in vaccination campaigns. Africa is a huge continent that has all these characteristics and at the same time has a very low vaccination rate. We cannot think of getting out of the pandemic emergency if we do not include Africa and all developing countries in a capillary vaccination campaign to prevent the emergence and spread of further and more dangerous variants that can evade both natural and vaccine-triggered immune responses and have higher mortality.
The scenario of a variant that is similarly transmissible to the omicron variant and has high mortality would be catastrophic and must be avoided at all costs. However, it is important to consider that even an increase in transmissibility with no change in lethality or hospitalisation rates could lead to the collapse of hospital emergency departments and health-care systems and an exceptionally high number of deaths. Moreover, promising and effective new therapies cannot yet have a substantial effect because they are scarce, expensive, and unlikely to have a measurable effect in the short term.
The fight against the virus must be waged on numerous open fronts: aggressive global vaccination campaigns (while also considering extending mandatory vaccination from some categories to the entire population), nonpharmacological interventions, strengthening emergency and critical care systems, and finding therapies that are effective at every stage of the disease. The road to normality is still very long.
References
- 1.
SARS-CoV-2 incidence and vaccine escape.
Lancet Infect Dis. 2021; 21: 913-914
- 2.
PPersistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.
Lancet Infect Dis. 2022; ()
- 3.
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Lancet. 2021; 398: 2093-2100
- 4.
Vaccine hesitancy in the COVID-19 era.
Lancet Infect Dis. 2021; 211086
- 5.
Importance of public health tools in emerging infectious diseases.
BMJ. 2021; 375n2374
- 6.
Where did “weird” omicron come from?.
Science. 2021; 3741179
- 7.
Omicron: a failure to act with a global focus will continue the proliferation of new variants of COVID-19.
BMJ. 2021; 375n3095
- 8.
Fair allocation of scarce therapies for COVID-19.
Clin Infect Dis. 2021; ()
Article Info
Publication History
Published: January 27, 2022
Identification
DOI: https://doi.org/10.1016/S1473-3099(22)00003-2
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirect